Skip to main content Skip to footer
American Family Children's Hospital
SHARE TEXT
 
Amye J. Tevaarwerk, MD close
3OX0WX1CxM8
Amye J. Tevaarwerk, MD
 

New Patients

Need help selecting a primary care doctor? Contact the Welcome Center for personal assistance.

For Referring Physicians

How to refer a patient

Amye J. Tevaarwerk, MD Print Friendly Page

Faculty, University of Wisconsin School of Medicine and Public Health

Amye Tevaarwerk, MD, obtained her medical degree from Washington University School of Medicine and completed an internship and residency in internal medicine at Barnes Jewish Hospital. Prior to entering clinical fellowship, she worked as a hospitalist for a year at Barnes Jewish Hospital in St. Louis. She completed a medical oncology fellowship at the University of Wisconsin. Her academic area of interest is breast oncology, with a focus on new drug development and women’s health issues as they relate to cancer survivorship. Dr. Tevaarwerk is a member of the UW Health Breast Center and part of Breast Disease-Oriented Working Group, through which multiple clinical trials in breast cancer are helping to find better treatments for those with cancer.

Specialties

Medical Oncology

Breast Cancer

Breast Center

Clinics

UW Carbone Cancer Center
(608) 265-1700 | (800) 323-8942 | Map
UW Carbone Cancer Center
(608) 266-6400 | (800) 323-8942 | Map
University Hospital
(608) 266-6400 | (800) 323-8942 | Map

Hospital Affiliation(s)

University Hospital
Veterans Hospital - Wm. S. Middleton Memorial

UW School of Medicine and Public Health

Department of Medicine

Professional Certifications and Education

Board Certification Medical Oncology
Fellowship University of Wisconsin Hospital and Clinics, Madison, WI
Residency Barnes-Jewish Hospital, St. Louis, MO
Internship Barnes-Jewish Hospital, St. Louis, MO
Medical School Washington University School of Medicine, St. Louis, MO

Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000.
Research

Dr. Tevaarwerk’s research interests include breast oncology and Phase I clinical trials.


PubMed Articles
Tevaarwerk AJ Sesto ME Continued Challenges to the Adoption and Implementation of Survivorship Care Plans. J Oncol Pract . 2018 Sep 7;:JOP1800378
[PubMed ID: 30192692]
Miller KD O'Neill A Gradishar W Hobday TJ Goldstein LJ Mayer IA Bloom S Brufsky AM Tevaarwerk AJ Sparano JA Le-Lindqwister NA Hendricks CB Northfelt DW Dang CT Sledge GW Jr Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer (E5103). J Clin Oncol . 2018 Sep 1;36(25):2621-2629
[PubMed ID: 30040523]
Litzelman K Keller AO Tevaarwerk A DuBenske L Adequacy of Depression Treatment in Spouses of Cancer Survivors: Findings From a Nationally Representative US Survey. J Gen Intern Med . 2018 Jun;33(6):869-876
[PubMed ID: 29404942]
Yeruva SLH Zhao F Miller KD Tevaarwerk AJ Wagner LI Gray RJ Sparano JA Connolly RM E2112: randomized phase iii trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer. NPJ Breast Cancer . 2018;4:1
[PubMed ID: 29354686]
Ma CX Suman V Goetz MP Northfelt D Burkard ME Ademuyiwa F Naughton M Margenthaler J Aft R Gray R Tevaarwerk A Wilke L Haddad T Moynihan T Loprinzi C Hieken T Barnell EK Skidmore ZL Feng YY Krysiak K Hoog J Guo Z Nehring L Wisinski KB Mardis E Hagemann IS Vij K Sanati S Al-Kateb H Griffith OL Griffith M Doyle L Erlichman C Ellis MJ A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III <i>PIK3CA</i>-Mutant ER-Positive and HER2-Negative Breast Cancer. Clin Cancer Res . 2017 Nov 15;23(22):6823-6832
[PubMed ID: 28874413]
Donohue S Haine JE Li Z Feldstein DA Micek M Trowbridge ER Kamnetz SA Sosman JM Wilke LG Sesto ME Tevaarwerk AJ Cancer Survivorship Care Plan Utilization and Impact on Clinical Decision-Making at Point-of-Care Visits with Primary Care: Results from an Engineering, Primary Care, and Oncology Collaborative for Survivorship Health. J Cancer Educ . 2017 Nov 2;
[PubMed ID: 29098650]
Donohue S Haine JE Li Z Trowbridge ER Kamnetz SA Feldstein DA Sosman JM Wilke LG Sesto ME Tevaarwerk AJ The Impact of a Primary Care Education Program Regarding Cancer Survivorship Care Plans: Results from an Engineering, Primary Care, and Oncology Collaborative for Survivorship Health. J Cancer Educ . 2017 Sep 20;
[PubMed ID: 28932992]
Tevaarwerk AJ Hocking WG Zeal JL Gribble M Seaborne L Buhr KA Wisinski KB Burkard ME Wiegmann DA Sesto ME Accuracy and Thoroughness of Treatment Summaries Provided as Part of Survivorship Care Plans Prepared by Two Cancer Centers. J Oncol Pract . 2017 May;13(5):e486-e495
[PubMed ID: 28221896]
Mirrielees JA Breckheimer KR White TA Denure DA Schroeder MM Gaines ME Wilke LG Tevaarwerk AJ Breast Cancer Survivor Advocacy at a University Hospital: Development of a Peer Support Program with Evaluation by Patients, Advocates, and Clinicians. J Cancer Educ . 2017 Mar;32(1):97-104
[PubMed ID: 26477478]
Rampurwala M Wisinski KB Burkard ME Ehsani S O'Regan RM Carmichael L Kim K Kolesar J Tevaarwerk AJ Phase 1b study of orteronel in postmenopausal women with hormone-receptor positive (HR+) metastatic breast cancer. Invest New Drugs . 2017 Feb;35(1):87-94
[PubMed ID: 27826831]
Tevaarwerk AJ Wisinski KB O'Regan RM Endocrine Therapy in Premenopausal Hormone Receptor-Positive Breast Cancer. J Oncol Pract . 2016 Nov;12(11):1148-1156
[PubMed ID: 27858538]
Neuman HB Jacobs EA Steffens NM Jacobson N Tevaarwerk A Wilke LG Tucholka J Greenberg CC Oncologists' perceived barriers to an expanded role for primary care in breast cancer survivorship care. Cancer Med . 2016 Sep;5(9):2198-204
[PubMed ID: 27356781]
Wisinski KB Xu W Tevaarwerk AJ Saha S Kim K Traynor A Dietrich L Hegeman R Patel D Blank J Harter J Burkard ME Targeting Estrogen Receptor Beta in a Phase 2 Study of High-Dose Estradiol in Metastatic Triple-Negative Breast Cancer: A Wisconsin Oncology Network Study. Clin Breast Cancer . 2016 Aug;16(4):256-61
[PubMed ID: 27133732]
Wisinski KB Tevaarwerk AJ Burkard ME Rampurwala M Eickhoff J Bell MC Kolesar JM Flynn C Liu G Phase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2+ Breast Cancer. Clin Cancer Res . 2016 Jun 1;22(11):2659-67
[PubMed ID: 27026198]
Neuman HB Steffens NM Jacobson N Tevaarwerk A Anderson B Wilke LG Greenberg CC Oncologists' Perspectives of Their Roles and Responsibilities During Multi-disciplinary Breast Cancer Follow-Up. Ann Surg Oncol . 2016 Mar;23(3):708-14
[PubMed ID: 26474556]
Tevaarwerk AJ Lee JW Terhaar A Sesto ME Smith ML Cleeland CS Fisch MJ Working after a metastatic cancer diagnosis: Factors affecting employment in the metastatic setting from ECOG-ACRIN's Symptom Outcomes and Practice Patterns study. Cancer . 2016 Feb 1;122(3):438-46
[PubMed ID: 26687819]
Sun W Chen K Terhaar A Wiegmann DA Heidrich SM Tevaarwerk AJ Sesto ME Work-related barriers, facilitators, and strategies of breast cancer survivors working during curative treatment. Work . 2016;55(4):783-795
[PubMed ID: 28059814]
Wisinski KB Cantu CA Eickhoff J Osterby K Tevaarwerk AJ Heideman J Liu G Wilding G Johnston S Kolesar JM Potential cytochrome P-450 drug-drug interactions in adults with metastatic solid tumors and effect on eligibility for Phase I clinical trials. Am J Health Syst Pharm . 2015 Jun 1;72(11):958-65
[PubMed ID: 25987691]
Ehsani S Strigel RM Pettke E Wilke L Tevaarwerk AJ DeMartini WB Wisinski KB Screening magnetic resonance imaging recommendations and outcomes in patients at high risk for breast cancer. Breast J . 2015 May-Jun;21(3):246-53
[PubMed ID: 25789917]
Andreason M Zhang C Onitilo AA Engel J Ledesma WM Ridolfi K Kim K Charlson JC Wisinski KB Tevaarwerk AJ Treatment differences between urban and rural women with hormone receptor-positive early-stage breast cancer based on 21-gene assay recurrence score result. J Community Support Oncol . 2015 May;13(5):195-201
[PubMed ID: 26029936]